Litifilimab
Based on 1 Customer Validation
Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2. Litifilimab induces internalization of BDCA2 receptors on the membrane of plasmacytoid dendritic cells, inhibits the TLR7/TLR9 signaling pathway, and suppresses the production of type I interferons. Litifilimab can be used in the research of systemic and cutaneous lupus erythematosus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.51%
- CAS No.: 2407378-48-5
- Masse moléculaire:146.6 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
BDCA2 |
Dectin-1 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CLEC4C Protein, Human can bind Litifilimab. The EC50 for this effect is 19.73 ng/mL.
Chemical Information
-
CAS No. 2407378-48-5
-
Appearance Liquid
-
Masse moléculaire 146.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Litifilimab]
-
Synonyms
BIIB059
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics Regulation of Type I Interferon in the Prevention and Treatment of Viral and Inflammatory Diseases
Regulation of type I interferon in the prevention and treatment of viral and inflammatory diseases refers to the control of interferon-α and interferon-β production, signaling, and biological activity to balance antiviral defense with immune homeostasis.
2026-06-18
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)